Veru Inc. Logo
  • About
    • About Veru
    • Our Scientific Efforts
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Publications & Meeting Presentations
  • Pipeline
    • Obesity and Overweight Program
    • Oncology Program – Breast Cancer
    • Infectious Disease Program
  • Products
    • FC2 Female Condom
  • Investors
    • Investors
    • Investor Kit
    • Press Releases
    • Stock Information
    • Financial Information
      • SEC Filings
      • Annual Reports
      • IRS Form 8937
    • Investor Presentations
    • Corporate Governance
      • Letter to Shareholders
      • Board Committees
      • Governance Documents
      • Policy for Director Attendance and for Shareholder Communications with Directors
  • News
  • Contact

IR Calendar

Investors

Investors

  • Investor Kit
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Presentations
    • Email Alerts
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • IRS Form 8937
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Ratios
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports & Proxy Statements
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board Committees
    • Governance Documents
    • Letter to Shareholders
    • Policy for Director Attendance and for Shareholder Communications with Directors

  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Presentations
  • Email Alerts

Oppenheimer Fall Healthcare Summit

September 21, 2021
Presentation
PDF
  • Email Alerts
  • Contacts
  • RSS News Feed

MIAMI  |  LONDON  |  MALAYSIA

Sign Up for Investor Alerts
© 2024 Veru Inc. | All Rights Reserved | Accreditation and Certificates | Privacy Notice | Anti-Trafficking Policy | Terms of Use | Contact Us
November 2022   US-CORP-2200001 | US-CORP-2200004

You are now leaving verupharma.com.

Back to VeruPharma.com
Continue

After submission, please check your email for our opt-in notice to complete your sign-up.

Go to Top